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Awareness
May Measurement Month (MMM), originally initiated as a temporary solution to ad-
dress the lack of blood pressure (BP) screening programs worldwide, emerged as an
effective annual campaign to increase the awareness of hypertension. MMM18, a
cross-sectional survey of volunteers aged 18 years was carried out during May 2018
predominantly in capital cities across Australia following the standard MMM protocol.
Blood pressure screening along with additional information including anthropometric
data and responses to questionnaires on demographic, lifestyle, and environmental
factors were collected from 3 352 individuals across Australia. After multiple imputa-
tion, 1 026 (30.6%) adult Australians had hypertension. Of the 2 936 individuals not
on antihypertensive treatment, 610 (20.8%) were hypertensive, and 237 (57.1%) of
the 416 individuals receiving antihypertensive treatment had uncontrolled BP. In line
with MMM17 results and other previous surveys, MMM18 revealed that close to one-
third of the screened population (30.6%) had hypertension, 57.1% of individuals
treated with BP-lowering medication remained uncontrolled indicating suboptimal
management of the condition in the majority of patients. Most importantly, only
49.0% of those with hypertension were aware of their elevated BP, highlighting lack
of awareness of elevated BP in nearly half of the affected population. Elevated BP
was directly associated with alcohol consumption, overweight, and obesity. Our find-
ings demonstrate the need for (i) continued efforts to increase BP awareness in the
population, (ii) optimization of BP management strategies, and (iii) tackling some of
the major contributors to BP elevation, including alcohol consumption and obesity.
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Introduction
High blood pressure (BP) is the 4th leading risk factor con-
tributing to disease burden and is responsible for 13.1% of
total deaths in Australia.1 In 2017–18, about one in three
people aged 18 and over (34%) had high BP comprising of
23% who had uncontrolled hypertension and 11% whose BP
was controlled using medication.2 The Australian burden of
disease database shows that hypertension contributes to
65% of the burden of hypertensive heart disease, 43% of
coronary heart disease, 41% of stroke, 38% of chronic kid-
ney disease, 32% of atrial fibrillation and flutter burden,
and 3.6% of dementia.1 Australia took part in May
Measurement Month 2017 (MMM17), a concerted effort of
International Society of Hypertension (ISH) expanding on
the World Hypertension Day which had been introduced by
the World Hypertension League (WHL)—to increase the
awareness of elevated BP globally. The Australian MMM17
findings demonstrated a prevalence of hypertension of
more than 30% with over 18% of hypertensive persons
untreated and over 40% inadequately treated. These
results provided motivation to repeat the campaign in 2018
to continue raising the awareness of hypertension in
Australia and emphasizing the need to control elevated BP.
Methods
The 2018 Australian MMM cross-sectional survey was car-
ried out throughout themonth of May with the involvement
of most states. The Dobney Hypertension Centre at the
University ofWestern Australia/Royal Perth Hospital served
as the national coordinating centre. One or more of the
state-wide leaders in the field of cardiovascular disease
and hypertension from each state were identified and in-
vited to participate and to co-ordinate the screening
efforts locally. Ethics approval was obtained, and volunteer
staff training, communication, and distribution of the
MMM18 protocols and materials occurred via the official
MMM website. Over 20 sites were set up in a wide range of
locations across Australia. Hypertension was defined as a
systolic BP of greater than or equal to 140mmHg or dia-
stolic BP of greater than or equal to 90mmHg, or in those
on antihypertensive medication. The mean of the second
and third BP readings was used in defining hypertension,
and in all analyses. Data were analysed centrally by the
MMM project team, and multiple imputation was per-
formed to impute the mean of the second and third read-
ings where this was missing, as described previously.3
Results
A total of 3 352 Australian participants were screened. The
mean age was 42 years, comprising multiple ethnicities in
varied proportions: 2 510 Whites (74.9%), 271 from South-
East Asia (8.1%), 172 from South Asia (5.1%), 161 from East
Asia (4.8%), 39 Black (1.2%), 27 Arabic (0.8%), 62 mixed
(1.8%), 95 other (2.8%), and 15 unknown (0.4%) with 1 915
female (57.1%) and 1 432 male (42.7%) participants. Of the
3 352 screened participants, 170 (5.1%) previously partici-
pated in MMM17, 416 (12.4%) were on antihypertensive
treatment, 150 (4.5%) reported having diabetes, 67 (2.0%)
reported a history of myocardial infarction, and 55 (1.6%)
reported a history of stroke. Two hundred and fifty-nine
(7.7%) respondents reported smoking, 1 516 (45.2%)
reported alcohol consumption once or more per week. The
mean body mass index (BMI) of respondents was 25.4 kg/m2
and 16 (0.8%) of female respondents reported being preg-
nant (Supplementary material online, Table S1). After im-
putation, of the 3 340 individuals for whom a mean of the
second and third reading was available, the age-
standardized and sex-standardized mean BP was 124.1/
79.7mmHg in those not on any antihypertensive medica-
tions, and 136.2/87.0mmHg in those on antihypertensive
medications.
In MMM18, of the 3 352 individuals screened throughout
the month of May, 1 026 (30.6%) had hypertension and only
503 (49%) of the hypertensive population were aware of
their condition. Of the 2 936 individuals not on antihyper-
tensive treatment, 610 (20.8%) were hypertensive, and 237
(57.1%) of the 416 individuals receiving antihypertensive
treatment had uncontrolled BP, leaving only 42.9% of indi-
viduals receiving antihypertensive treatment with con-
trolled BP and 17% of the overall hypertensive population
having BP under control. The association between age and
sex with systolic BP in Australians who were not receiving
antihypertensive treatment showed a linear increase, with
the mean BP being lower in females. For diastolic BP, the
relationship showed an inverted U shapewith highest levels
at age 50–55 years in males and 55–60 years in females
(Supplementary material online, Figure S1). After adjust-
ment for age and sex (allowing for an interaction), signifi-
cantly higher systolic and diastolic BP was apparent in
patients with previously diagnosed hypertension, and those
on antihypertensive treatment, emphasizing the need for
more assertive treatment in such high-risk patients.
Discussion
As part of the MMM18 campaign in Australia, 3 352 partici-
pants of multi-ethnic background were screened. In
Australia, MMM18 detected that prevalence of hyperten-
sion was very similar to the MMM17 (31.2%) and Global 2017
and 2018 data (34.9% and 33.4%, respectively). Of the
drug-naı¨ve participants screened, MMM18 identified 20.8%
with high BP in Australia and 18.4% globally. Furthermore,
57.1% of the individuals who received treatment had
uncontrolled BP which is a substantially higher rate com-
pared to the 40.1% seen globally.5 These results are indica-
tive of the high prevalence of hypertension and relatively
low control rates of hypertension in Australia, on par with
the worldwide and previous national estimates.3–5
Importantly, only 49% of the screened individuals with hy-
pertension were aware of their elevated BP, which is some-
what close to the 46.5% awareness recorded by the PURE
study6 but lower than 59.5% recorded by the global
MMM18.5 The findings of lower BP in pregnant women, the
usual patterns of systolic and diastolic BP with age, and the
association of alcohol consumption with increased BP were
consistent with the national and global MMM17-18 data.3–5
Well-established associations seen between higher BP and
increasing age,7 BMI,8 alcohol status,9 and lower BP in preg-
nancy10 match the global data and strongly reaffirm the va-
lidity of the data obtained by this screening campaign. Our
findings demonstrate the need for (i) continued efforts to
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increase BP awareness in the population, (ii) optimization
of BP management strategies, and (iii) tackling some of the
major contributors to BP elevation including alcohol con-
sumption, overweight, and obesity.
MMM limitations include the assessment of BP based on
single set of three readings on a single occasion, thereby in-
creasing the possibility of false negatives but more likely
false positives in the diagnoses of hypertension. By design,
MMM18 in Australia was not intended to be based on repre-
sentative samples of the Australian states where screening
took place predominantly in the major cities obscuring the
true prevalence. The BP recordings were obtained in di-
verse environments with one-third of the screening sites
set up in healthcare facilities which could result in self-
selection of a greater proportion of hypertensive partici-
pants. In addition, the effect of diet and lifestyle advice
given to hypertensive participants and the post-survey im-
pact on awareness could not be assessed in this cross-
sectional design.
Supplementary material
Supplementary material is available at European Heart
Journal Supplements online.
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